Home › NDC Lookup › Ingredients › Dimenhydrinate › 70677-1087-01
Motion Sickness Dimenhydrinate 50 mg Tablet, 12-count — NDC 70677-1087-01 package photo

Motion Sickness Dimenhydrinate 50 mg Tablet, 12-count

by Strategic Sourcing Services LLC · 2 BLISTER PACK in 1 CARTON (70677-1087-1) / 6 TABLET in 1 BLISTER PACK
NDC 70677-1087-01
🏷️ FDA NDC (as labeled) 70677-1087-1 billing pads the package segment with a zero
OTC On market Non-controlled
🗂️ Data synced Sep 3, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 70677-1087-1
Product NDC 70677-1087
11-digit billing NDC 70677108701
NCPDP billing unit EA — each (per item)
RxCUI 198603
UNII JB937PER5C
UPC 0010939956231
Application # M009
SPL Set ID be8f91d4-6e4f-4d47-93e9-7fb91160b7df
Established class (EPC) Histamine-1 Receptor Antagonist
Mechanism of action Histamine H1 Receptor Antagonists
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-05-04
Route ORAL
Dosage form TABLET
Substance DIMENHYDRINATE
GCN Seq No 004720
GCN 18231
HICL code 004603
Ingredient (HICL) Dimenhydrinate
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6J
Therapeutic class — specific (HIC3) Antiemetic/Antivertigo Agents
AHFS code 04:04.00.00
AHFS class First Generation Antihistamines
FDB label name FT MOTION SICKNESS 50 MG TAB
FDB brand name Motion Sickness
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 70677-1087-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70677-1087-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Aminoalkyl ethers class.

Drug family (ATC) Aminoalkyl ethers
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerStrategic Sourcing Services LLC
FDA applicationM009 (OTC MONOGRAPH DRUG)
Labeler code70677
First marketedMay 2023
Product typeHuman Otc Drug
Portfolio316 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name FT MOTION SICKNESS 50 MG TAB Ingredient Dimenhydrinate
📖 What it is MedlinePlus · NLM

Dimenhydrinate is used to prevent and treatmotion sickness. Dimenhydrinate is in a class of medications called antihistamines. It works by preventing problems with body balance.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Dimenhydrinate works by calming your inner ear when it gets overstimulated during travel — that's the root cause of the nausea, vomiting, and dizziness you feel. It's proven effect...
  • What exactly does dimenhydrinate do — and will it stop my motion sickness?
  • Drowsiness is the most common side effect — it's very real and something to plan for. Avoid driving or operating machinery until you know how dimenhydrinate affects you. Alcohol, s...
  • It can be used in children as young as 2 years old — but only with a doctor's guidance for children under 2, and never in newborns. In young children especially, antihistamine over...
📖 Read our full Dimenhydrinate guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
ShapeRound
Imprint44;198
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.

6 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescroscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid 

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.054 $0.65 / 12 tablets
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2023 Dec 2025 Apr 2026 Aug 2026 $0.072 $0.048
Flat over the last 12 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Dimenhydrinate 50 mg 70000-0404-01 LEADER/ 12 tablets $0.054 — Availability likely save 1%
Driminate 50 mg 00904-2051-59 Major 100 tablets $0.054 — Availability likely —
Dimenhydrinate 50 mg 00904-6772-12 Major 12 tablets $0.054 — Availability likely —
Motion Sickness Relief 50 mg 46122-0536-53 Amerisource 12 tablets $0.054 — Availability likely —
Motion Sickness Relief 50 mg 70000-0749-01 Cardinal 12 tablets $0.054 — Availability likely —
Motion Sickness 50 mgthis 70677-1087-01 Strategic 12 tablets $0.054 — Availability likely —
Motion Sickness Relief 50 mg 83324-0032-12 Chain 12 tablets $0.054 — Availability likely —
Motion Sickness Relief 50 mg 00363-1980-08 Walgreen 24 tablets — — FDA listed —
Gravol 50 mg 10237-0941-10 Church 10 tablets — — FDA listed —
Motion Sickness 50 mg 11673-0198-02 Target 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 11673-0354-24 TARGET 24 tablets — — FDA listed —
Motion Sickness Relief 50 mg 11822-0198-02 Rite 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 36800-0930-12 Topco 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 49035-0981-12 Wal-Mart 100 tablets — — FDA listed —
Motion Sickness 50 mg 50804-0198-02 Geiss, 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 50844-0199-02 L.N.K. 12 tablets — — FDA listed —
Motion Sickness 50 mg 59779-0198-02 CVS 12 tablets — — FDA listed —
Dramamine Original Formula 50 mg 63029-0901-01 Medtech 36 tablets — — FDA listed —
Motion Sickness Relief 50 mg 63941-0198-02 Valu 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 67091-0118-12 WinCo 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 69168-0408-86 Allegiant 12 tablets — — FDA listed —
Dimenhydrinate 50 mg 69842-0206-12 CVS 12 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2023
On the market since
May 2023
📍
2026
Currently FDA-listed
3 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📊 Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)

Medicare Part D (outpatient prescription) spending for Dimenhydrinate (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Dimenhydrinate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$4K
Claims incl. refills
15
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$269.22
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Motion Sickness (this brand).

Top reported reactions

Nausea829
Febrile Neutropenia813
Fatigue614
Vomiting525
Dizziness478
Pyrexia438
Headache433

Age at onset

Neonate35
Infant56
Child194
Adolescent97
Adult818
Elderly422

Reporter sex

7,405 reports
Male · 37%
Female · 63%
Unknown · 0%

Serious outcomes

Hospitalization3,528
Life-threatening864
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 897 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
70677-1087-01 You're viewing this 2 BLISTER PACK in 1 CARTON (70677-1087-1) / 6 TABLET in 1 BLISTER PACK 2023-05-04 Active

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose
🎯 Indications and Usage 15 words ▾

Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness

⏱️ Dosage and Administration 122 words ▾

Directions do not take more than directed to prevent motion sickness, the first dose should be taken 1/2 to 1 hour before starting activity to prevent or treat motion sickness, see below: adults and children 12 years and over take 1 to 2 tablets every 4-6 hours do not take more than 8 tablets in 24 hours, or as directed by a doctor children 6 to under 12 years give 1/2 to 1 tablet every 6-8 hours do not give more than 3 tablets in 24 hours, or as directed by a doctor children 2 to under 6 years give 1/2 tablet every 6-8 hours do not give more than 1 1/2 tablets in 24 hours, or as directed by a doctor

⚠️ Warnings 117 words ▾

Warnings Do not use for children under 2 years of age unless directed by a doctor. Ask a doctor before use if you have glaucoma a breathing problem such as emphysema or chronic bronchitis difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers. When using this product marked drowsiness may occur alcohol, sedatives, and tranquilizers may increase drowsiness avoid alcoholic beverages use caution when driving a motor vehicle or operating machinery If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

📦 Storage and Handling 45 words ▾

Other information each tablet contains: calcium 35 mg TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN store at 25ºC (77ºF); excursions permitted between 15º-30ºC (59º-86ºF) protect from moisture see end flap for expiration date and lot number

🧪 Active Ingredient 8 words ▾

Active ingredient (in each tablet) Dimenhydrinate 50 mg

🧪 Inactive Ingredients 16 words ▾

Inactive ingredients croscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid

🎯 Purpose 2 words ▾

Purpose Antiemetic

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 70677-1086-01 · Strategic 70677-1088-01 · Strategic →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.